Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. / Frederiksen, B.; Specht, L.; Henrichsen, J.; Pedersen, F.K.; Pedersen-Bjergaard, J.
I: European Journal of Haematology, Bind 43, Nr. 1, 1989, s. 45-49.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease
AU - Frederiksen, B.
AU - Specht, L.
AU - Henrichsen, J.
AU - Pedersen, F.K.
AU - Pedersen-Bjergaard, J.
N1 - DA - 19890928IS - 0902-4441 (Print)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Antibodies, Bacterial)RN - 0 (Antigens, Bacterial)RN - 0 (Bacterial Vaccines)SB - IM
PY - 1989
Y1 - 1989
N2 - Antibody response to pneumococcal vaccination was studied in 76 patients with Hodgkin's disease (HD) before, during and at different time intervals after cessation of therapy. All patients were in pathological stage I and II following explorative laparatomy with splenectomy. The increase in antibody response was compared to the findings in 12 healthy volunteers with the aim of establishing the optimal time for vaccination. Serum antibodies against 6 of the pneumococcal polysaccharide antigens (types 1, 4, 7F, 14, 18C and 23F) contained in the vaccine were determined by an ELISA. Antibody response to pneumococcal type antigens was similar in healthy adults and in patients with early stage HD before therapy. After treatment, postvaccination antibody response became negligible. Even up to 7 years after cessation of therapy patients were not able to raise a significant antibody response Udgivelsesdato: 1989/7
AB - Antibody response to pneumococcal vaccination was studied in 76 patients with Hodgkin's disease (HD) before, during and at different time intervals after cessation of therapy. All patients were in pathological stage I and II following explorative laparatomy with splenectomy. The increase in antibody response was compared to the findings in 12 healthy volunteers with the aim of establishing the optimal time for vaccination. Serum antibodies against 6 of the pneumococcal polysaccharide antigens (types 1, 4, 7F, 14, 18C and 23F) contained in the vaccine were determined by an ELISA. Antibody response to pneumococcal type antigens was similar in healthy adults and in patients with early stage HD before therapy. After treatment, postvaccination antibody response became negligible. Even up to 7 years after cessation of therapy patients were not able to raise a significant antibody response Udgivelsesdato: 1989/7
M3 - Tidsskriftartikel
VL - 43
SP - 45
EP - 49
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 1
ER -
ID: 19371443